FDA approves Alexion’s Ultomiris for another rare blood disease
(Reuters) – The U.S. Food and Drug Administration on Friday approved Alexion Pharmaceuticals Inc’s treatment for a second rare blood…
Patent court to review Alexion’s Soliris patents on Amgen challenge
(Reuters) – The U.S. patent office will review patents on Alexion Pharmaceuticals Inc’s blood disorder treatment Soliris, after Amgen Inc…
Eton’s conjunctivitis treatment fails to win FDA nod; shares tumble
(Reuters) – Eton Pharmaceuticals Inc said on Friday that the U.S. Food and Drug Administration declined to approve its treatment…
FDA approves expanded label for Regeneron/Sanofi’s cholesterol drug
(Reuters) – The U.S. Food and Drug Administration on Friday approved Regeneron Pharmaceuticals Inc’s cholesterol drug Praluent as a treatment…
U.S. FDA approves Alexion Pharma’s blood disorder drug
(Reuters) – The U.S. Food and Drug Administration has approved Alexion Pharmaceuticals Inc’s blood disorder drug Ultomiris, the pharma regulator’s…
Regeneron/Sanofi cut heart drug price to $4,500-$6,600 for Express Scripts
(Reuters) – Regeneron Pharmaceuticals Inc and Sanofi SA will slash the price of their expensive cholesterol drug for Express Scripts…
Biotech M&A rolls on as Alex ion snaps up Wilson for $855 mln
(Reuters) – Alex ion Pharmaceuticals has agreed to buy Sweden’s Wilson Therapeutics for 7.1 billion Swedish crowns ($855 million), boosting…